Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8238
Revised: October 4, 2013
Accepted: October 17, 2013
Published online: December 7, 2013
Processing time: 98 Days and 15.1 Hours
Nonalcoholic fatty liver disease (NAFLD) has been recognized as the most common liver metabolic disease, and it is also a burgeoning health problem that affects one-third of adults and is associated with obesity and insulin resistance now. Thyroid hormone (TH) and its receptors play a fundamental role in lipid metabolism and lipid accumulation in the liver. It is found that thyroid receptor and its isoforms exhibit tissue-specific expression with a variety of functions. TRβ1 is predominantly expressed in the brain and adipose tissue and TRβ2 is the major isoform in the liver, kidney and fat. They have different functions and play important roles in lipid metabolism. Recently, there are many studies on the treatment of NAFLD with TH and its analogues. We review here that thyroid hormone and TR are a potential target for pharmacologic treatments. Lipid metabolism and lipid accumulation can be regulated and reversed by TH and its analogues.
Core tip: The clinical findings that nonalcoholic fatty liver disease (NAFLD) patients have more prevalence of subclinical hypothyroidism and patients with hypothyroidism may develop fatty liver give the evidence that dyslipidemia and fatty liver have some relationship with thyroid dysfunction, and thyroid hormone and its receptor may be a therapeutic target for NAFLD. We review here that thyroid hormone and TR are a potential target for pharmacologic treatments that can benefit NAFLD patients a lot.